The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia

CNS Drugs

Volumn 27, Issue 8, 2013, Pages 625-636

  Awad, A George ^a,b   Voruganti, Lakshmi N P ^c  

^a HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Psychiatry   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL STATUS; HUMAN; MEDICATION COMPLIANCE; NEUROLOGIC DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SELF REPORT; SOCIAL INTERACTION;

EID: 84880811606     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0070-1     Document Type: Review

References (76)

1. U.S. Food and Drug Administration Guidance for Industry. Patient-Reported Outcome Measures; use in medical product development to support labelling claims, FDA (2006).
2. Voruganti LNP, Heselgrave RS, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the question of subjectivity with the question of reliability. Psychol Med. 1998;28:165-72.
3. Awad AG, Voruganti LNP. The subjective/objective dichotomy: relevance to nosology, research and management. In: Gaebel W, editor. Zukunftsperspekiven in psychiatries und psychothezapie. Dormstadt: Stienkopff Verlog; 2002. p. 21-7.
4. Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient related quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178-86.
5. Awad AG, Voruganti LNP. Intervention research in psychosis: issues related to assessment of quality of life. Schizophr Bull. 2000;26:557-64.
6. Voruganti LNP, Slomka P, Zabel P, et al. Subjective effect of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D2 binding ratios in SPECT imaging. Neuropsychopharmacology. 2001;25:642-50.
7. De Haan L, Lavalaye J, Linszend D, et al. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019-20.
8. Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia: findings from in vivo SPECT study. Schizophr Res. 2006;88:179-86.
9. Mizrahi R, Mamo D, Pausion P, et al. The relationship between subjective well-being and dopamine D2 receptors in patients treated with dopamine partial agonist and a full antagonist antipsychotic. Int J Neuropsychopharmacol. 2009;5:715-21.
10. Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: What are they and are they being achieved? CNS Drugs. 1995;4:8-16.
11. Ritsner M, Kurs R. Impact of antipsychotic agents and their side-effects on the quality of life in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2002;2:89-98.
12. Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877-93.
13. Zacher JL, Holmes JC. Second-generation antipsychotics: a review of recently approved agents and drugs in the pipeline. Formulary. 2012;47:106-12
14. Tuanainen A, Wahlbeck K. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000; (2): CD000966.
15. Citrome L. Iloperidone, asenapine and lurasidone: a brief overview of three new second-generation antipsychotics. Postgrad Med. 2011;123:153-62.
16. Edwards SJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparisons of randomized controlled trials. Clin Ther. 2009;31:1345-59.
17. Agency for Health Care Research and Quality (AHRQ). First generation versus second generation antipsychotics in adults: Comparative effectiveness. Executive Summary, Publication No. 12 - EHC054-EF, 2012. http://www. effectivehealthcare.ahrg.gov/reports/final.cfm.
18. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia - an update. Pharmacoeconomics. 2012;30:183-95.
19. Awad AG, Voruganti LNP, Heselgrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. 1997;6:21-6.
20. Mencaccic on behalf of all investigators. Efficacy and tolerability of switching to ziprasidone in Italian patients with acute exacerbation of schizophrenia - an open-label study. Pharmacopsychiatry. 2012;45:236-40.
21. Huang M-W, Yang T-T, Ten P-R, et al. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol. 2012;12:1-11.
22. Grootens KP, van Vellen NM, Peuskens J, et al. Ziprasidone versus olanzapine in recent-onset schizophrenia and schizoaffective disorder - double-blind randomized controlled trial. Schizophr Bull. 2011;37:352-61.
23. Jui-Kang T, Wen-Kuo L, For-Wey L. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343-51.
24. Liu-Seifert H, Osuntokun O, Godfrey J, et al. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369-77.
25. Docherty JP, Baker RA, Eudicone J, et al. Effect of aripiprazole versus haloperidone on PANSS Prosocial items in early episode patients with schizophrenia. Schizophr Res. 2010;120:199-203.
26. Ming-Hong H, Wei-Wen L, Shao-Tsu C, et al. A 64-week multicentre, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann Gen Psychiatry. 2010;9:35. doi: 10.1186/1744-859X-9-35.
27. Shoemaker J, Naber D, Vrifland P, et al. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138-46.
28. Stahl SM, Malla A, Newcomer JW, et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Clin Psychopharmacol. 2010;30:425-50.
29. Canuso C, Grinspan A, Kalali A, et al. Medication satisfaction in schizophrenia: a blinded initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010;25:155-64.
30. Burns P, Morasini P, Gagnon DD, et al. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of pooled analysis of three phase III trials of paliperidone extended release tablets. Clin Ther. 2010;32:275-92.
31. de Oliveira IR, Elkis H, Gattaz WF, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized study versus haloperidol. CNS Spectr. 2009;14:93-102.
32. Kobayashi H, Morita K, Takeshi K, et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol. 2009;5:421-5.
33. Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week double-blind treatment with risperidone versus haloperidol. Int J Neuropsychopharmacol. 2009;9:1233-48.
34. Kim SW, Shin JS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32:243-9.
35. Schooler N. Long-term treatment with asenapine versus olanzapine in subjects with predominant persistent negative symptoms of schizophrenia. 2009, Abstract SCR-26-076.
36. Taylor D, Hanssens L, Loze JY, et al. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole versus standard of care, results from the STAR study. J Eur Psychiatry. 2008;23:336-43.
37. Nasralla H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161:213-24.
38. Rossi A, Vita A, Tiradritti P, et al. Assessment of clinical and metabolic status, and subjective well-being in schizophrenia patients switched from typical to atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;4:216-22.
39. Ritsner M, Yorkov V, Ratner Y, et al. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia - a 12-month open-label, flexible-dose naturalistic observational study of patients undergoing usual care. Progr Neuro-Psycho Pharmacol Biol Psychiatry. 2007;31:1470-7.
40. Arang C, Gomez-Beneyto M, Brenlla J, et al. A 6-month prospective observational, naturalistic uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Euro Neropsychopharmacol. 2007;17:456-63
41. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients - Schizophrenia Trial of aripiprazole: (STAR) study. Eur Psychiatry. 2007;7:433-43.
42. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. AM J Psychiatry. 2007;164:428-36.
43. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment resistant schizophrenia: a double-blind comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-23.
44. Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability and safety of aripiprazole in patients with schizophrenia or schizoaffective disorder: results of multicentre observational trial. Eur Psychiatry. 2007;22:195-202.
45. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia - an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:373-7.
46. Tandon R, Marcus RN, Stock EG, et al. A prospective multicentre randomized parallel-group open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness study trial with aripiprazole (BETA). Schizophr Res. 2006;84:77-89.
47. Rosenbeck RA, Leslie D, Sendelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080-9.
48. Philips GA, Van Brunt DL, Roychowdhury SM, et al. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1397-403.
49. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879-87.
50. Loebel A, Siu C, Romanos S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357-64.
51. Voruganti LNP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berlin). 2004;171:121-32.
52. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187-90.
53. Hogan TP, Awad AG, Eastwood MR. A self-report predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol Med. 1983;13:177-83.
54. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination of two measures. Psychol Med. 1992;22:347-52.
55. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr bull. 1993;19:609-18.
56. Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid abuse in schizophrenia and the emerging science of subjective tolerability. J Dual Design. 2005;1:83-95
57. Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmcoecon Outcomes Res. 2010;10:1-4.
58. Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life and other clinical variables. Int J Clin Psychopharmacol. 1995; 10(suppl)30: 123-133.
59. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37-48.
60. Petall EA, Cooper H, Robinson C. The effects of choice on intrinsic motivation and related outcomes: a meta analysis of research findings. Psychol Bull. 2008;134:270-300.
61. Rosenbeck R, Stroup S, Keefe RS, et al. Measuring outcome priorities and preferences in people with schizophrenia. Brit J Psychiatry. 1005;187:529-36.
62. Awad AG. Antipsychotic medications: how satisfied are our patients? Clear Perspective, Management Issues in Schizophrenia 1999; 2: 1-6.
63. Rofail D, Gray R, Gowrnay K, et al. The development and internal consistency of the satisfaction with antipsychotic scale. Psychol Med. 2005;35:1063-72.
64. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire. Psychopharmacol Bull. 1993;29:321-8.
65. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118:271-8.
66. Brissos S, Molodynski A, Dias VV, et al. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry. 2011;10:1-7.
67. Figueira M, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr Opin Psychiatry. 2001;24:91-9.
68. Heselgrave RJ, Awad AG, Voruganti LNP. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neuro Sci. 1997;22:235-43.
69. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008;21:630-9.
70. Bell M, Tsang HW, Greig TE, et al. Neurocognition, social cognition, perceived social discomfort and vocational outcomes in schizophrenia. Schizophr Bull. 2009;35:738-47.
71. Hugh D, Nuamah IF, Lim P, et al. Independent effect of paliperidone extended release on social functioning beyond its effects on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol. 2009;29:496-7.
72. Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235-45.
73. Kawata T, Rivicki D. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17:1247-56.
74. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:585-8.
75. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2011;. doi: 10-1007/s11136-011-0054-x.
76. Staniszewska S, Haywood K, Brett J, et al. Patient and public involvement in patient-reported outcome measures: evolution not revolution. Patient. 2012;5:79-87.